Oaktree Acquisition Corp. III Life Sciences
OACC
$10.47
$0.000.00%
NASDAQ
| 09/30/2024 | |||||
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | -- | ||||
| Total Receivables | -- | ||||
| Inventory | -- | ||||
| Prepaid Expenses | -- | ||||
| Finance Division Loans and Leases Current | -- | ||||
| Total Finance Division Other Current Assets | -- | ||||
| Other Current Assets | -- | ||||
| Total Current Assets | -- | ||||
|
|
|||||
| Total Current Assets | -- | ||||
| Net Property, Plant & Equipment | -- | ||||
| Long-term Investments | -- | ||||
| Goodwill | -- | ||||
| Total Other Intangibles | -- | ||||
| Finance Div Loans & Leases LT | -- | ||||
| Total Finance Div Other LT Assets | -- | ||||
| Total Other Assets | 558.76% | ||||
| Total Assets | 558.76% | ||||
|
|
|||||
| Total Accounts Payable | -- | ||||
| Total Accrued Expenses | -60.34% | ||||
| Short-term Debt | -- | ||||
| Current Portion of Long-Term Debt/Capital Leases | -- | ||||
| Finance Division Debt Current | -- | ||||
| Total Finance Division Other Current Liabilities | 657.92% | ||||
| Total Other Current Liabilities | 657.92% | ||||
| Total Current Liabilities | 640.60% | ||||
|
|
|||||
| Total Current Liabilities | 640.60% | ||||
| Long-Term Debt | -- | ||||
| Short-term Debt | -- | ||||
| Capital Leases | -- | ||||
| Finance Division Debt Non Current | -- | ||||
| Total Finance Division Other Non Current Liabilities | -- | ||||
| Total Other Liabilities | -- | ||||
| Total Liabilities | 640.60% | ||||
|
|
|||||
| Common Stock & APIC | 0.00% | ||||
| Retained Earnings | -176.44% | ||||
| Treasury Stock & Other | -- | ||||
| Total Common Equity | -403.95% | ||||
|
|
|||||
| Preferred Stock Redeemable | -- | ||||
| Preferred Stock Non Redeemable | -- | ||||
| Preferred Stock Convertible | -- | ||||
| Preferred Stock, Others | -- | ||||
| Total Preferred Equity | -- | ||||
|
|
|||||
| Total Common Equity | -403.95% | ||||
| Total Preferred Equity | -- | ||||
| Total Minority Interest | -- | ||||
| Total Equity | -403.95% | ||||
|
|
|||||